ERIS Lifesciences Ltd
ERIS Lifesciences Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #50 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
2 of 3 strong
The short version
DBF segment delivered 14% revenue growth in Q1 FY27; aiming for 3% above market growth (~14% vs 11% market). Q1 FY27 Profit After Tax grew by 14.5%, with EPS at INR 10.3, indicating strong profitability (Page 16). - Domestic formulations (DBF) segment expects sustained 14%+ revenue growth, targeting 300 bps above market growth (~14% vs.
From ERIS Lifesciences Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- DBF segment delivered 14% revenue growth in Q1 FY27; aiming for 3% above market growth (~14% vs 11% market).
- Long-term goal to structurally achieve top-tier growth through portfolio shift towards biologics and insulin.
- Insulin franchise shows strong market share gains and has significant growth potential from existing products and pipeline.
- Semaglutide brand SUNDAE has captured 20% volume and 14% value market share in its first quarter.
- Domestic formulations expected to see gross margin improvement by Q3-Q4 FY27 aiding EBITDA margins.
- OAD segment growth expected to improve to 5-6% with product launches and ramp-up.
- No inorganic growth activities planned currently; focus on organic growth and manufacturing capabilities.
2 more points from ERIS Lifesciences Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what ERIS Lifesciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- CapEx for Q1 FY27 stood at INR 88 crores.
- Focus on manufacturing expansion with priority given to the Bhopal facility; commercialization expected in August with ramp-up by end of Q3 FY27.
- Investment in manufacturing technology and facilities continues to be a priority over acquisitions for this year and the start of next year.
- No major acquisitions planned currently; emphasis is on organic growth and strengthening manufacturing capacity.
2 more points from ERIS Lifesciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what ERIS Lifesciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what ERIS Lifesciences Ltd said on order book & pipeline — free account, 30 seconds.
ERIS Lifesciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹892 Cr, net profit ₹187 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What ERIS Lifescience's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
ERIS Lifesciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were ERIS Lifesciences Ltd Q1 FY27 results?
DBF segment delivered 14% revenue growth in Q1 FY27; aiming for 3% above market growth (~14% vs 11% market). Q1 FY27 Profit After Tax grew by 14.5%, with EPS at INR 10.3, indicating strong profitability (Page 16). - Domestic formulations (DBF) segment expects sustained 14%+ revenue growth, targeting 300 bps above market growth (~14% vs.
What is ERIS Lifesciences Ltd share price analysis?
ERIS Lifesciences Ltd currently shows a below-average growth signal. The stock trades at a P/E of 28.1 with a market cap of ₹18,407 Cr. Investors should review the full earnings analysis for detailed insights.
Is ERIS Lifesciences Ltd planning capital expenditure?
CapEx for Q1 FY27 stood at INR 88 crores.
Keep ERIS Lifesciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.